IPG Photonics Corporation has entered into a Put Option Agreement for the proposed acquisition of 100% of Lumibird Medical from its parent company, Lumibird S.A. The transaction is valued at €300 million, to be paid in cash at closing, with an additional contingent earnout of up to €50 million based on future performance. The acquisition is expected to be financed with cash on hand and is targeted to close in the fourth quarter of 2026.
Key Details
- Acquisition Target: 100% of the outstanding shares of Lumibird Medical, a French medical technology company and subsidiary of Lumibird S.A.
- Financial Terms: €300 million purchase price on a cash-free, debt-free basis, plus a potential cash earnout of up to €50 million based on achieving certain performance metrics in 2026 and 2027.
- Timeline & Conditions: The closing is expected in Q4 2026, subject to customary conditions, including the completion of a works council consultation process by the seller and authorization under the French foreign direct investment regime.
- Agreement Structure: The transaction is structured as a put option, where IPG Photonics is irrevocably committed to purchase the shares upon the seller's exercise of the option after fulfilling its consultation obligations.